A massive treatment gap exists between who qualifies for today's most transformative metabolic medicines and who actually receives them — and a new population-level analysis makes that gap impossible to ignore. For the roughly 50 million Americans on Medicare, understanding this disconnect has direct implications for cardiovascular risk, metabolic disease burden, and long-term healthcare costs.
Analyzing 100% of Medicare fee-for-service claims data across 2023–2024 — a cohort of over 16.4 million Part D beneficiaries — researchers found that 35.1% already have at least one condition for which GLP-1 receptor agonists are currently covered: Type 2 diabetes, established cardiovascular disease with overweight or obesity, obstructive sleep apnea with obesity, or metabolic dysfunction-associated steatohepatitis. Despite qualifying, only 16.5% of those eligible have ever filed a GLP-1 claim. Meanwhile, 76.9% of all beneficiaries carry at least one current or prospective GLP-1 indication, and an additional 407,085 currently ineligible patients could gain access if Medicare expanded coverage to include heart failure with preserved ejection fraction, chronic kidney disease, psoriasis, or knee osteoarthritis.
This analysis functions less as a clinical study and more as a policy stress test, but its health implications are profound. The 83.5% treatment gap among already-eligible patients likely reflects a collision of cost barriers, prescriber inertia, supply constraints, and patient hesitancy — none of which will resolve through coverage expansion alone. The finding that obesity-only patients remain excluded under current policy, while those with secondary comorbidities gain entry through a diagnostic back door, exposes an awkward paradox: Medicare may soon cover GLP-1s for knee pain before covering them for the obesity driving that pain. From a longevity standpoint, GLP-1 receptor agonists are increasingly linked to reductions in all-cause mortality, cardiovascular events, and kidney disease progression — making the access gap a measurable lifespan issue, not merely a formulary question. This is a confirmatory but scale-setting finding that should anchor any serious conversation about metabolic health equity in older adults.